IRIDEX Announces Fourth Quarter and Full Year 2013 Conference Call and Release
MOUNTAIN VIEW, Calif., Feb. 20, 2014
MOUNTAIN VIEW, Calif., Feb. 20, 2014 /PRNewswire/ --IRIDEX Corporation
(NASDAQ: IRIX) today announced that it will release its fourth quarter and
full year 2013 financial results after the market closes on Thursday, February
27, 2014. In conjunction with the release, the Company will host a conference
call with the investment community at 5:00 p.m. Eastern Time on Thursday,
February 27, 2014 to discuss the results of the quarter and full year and
other business developments.
Interested parties may access the live conference call via telephone by
dialing (888) 549-7880 (U.S.) or (480) 629-9770 (International) and quoting
Conference ID 4669674, or by visiting the Company's website at
www.iridex.com. A telephone replay will be available beginning on Thursday,
February 27, 2014 through Friday, March 7, 2014 by dialing (800) 406-7325
(U.S.) or (303) 590-3030 (International) and entering Access Code 4669674.
IRIDEX Corporation was founded in 1989 and is a worldwide leader in
developing, manufacturing, and marketing innovative and versatile laser-based
medical systems, delivery devices and consumable instrumentation for the
ophthalmology market. We maintain a deep commitment to the success of our
customers, with comprehensive technical, clinical, and service support
programs. IRIDEX is dedicated to a standard of excellence, offering superior
technology for superior results. IRIDEX products are sold in the United States
through both direct and independent sales forces and internationally through a
combination of a direct sales force and a network of approximately 70
independent distributors into over 100 countries. For further information,
visit the Company's website at http://www.iridex.com.
SOURCE IRIDEX Corporation
Contact: Company: Jim Mackaness, CFO & COO, 650-940-4700 or Investor
Relations: Rene Caron, Allen & Caron, 949-474-4300, email@example.com
Press spacebar to pause and continue. Press esc to stop.